RecruitingPhase 1NCT06994676
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Crossbow Therapeutics, Inc.
- Principal Investigator
- Briggs Morrison, MDCrossbow Therapeutics, Inc.
- Intervention
- CBX-250(drug)
- Enrollment
- 72 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2027
Study locations (11)
- City of Hope, Duarte, California, United States
- Stanford Medical Center, Palo Alto, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Northwestern Medicine, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- Sarah Cannon Cancer Institute, Nashville, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06994676 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05233618Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Karen Ballen, MD